Hap Trading, LLC Alaunos Therapeutics, Inc. Call Options Transaction History

Hap Trading, LLC

10 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2022 Feb 14, 2023	BUY	$0.5 - $261.0 $14,750 - $7.7 Million	29,500 Added 63.03%	76,300 $2,000
Q3 2022 Nov 14, 2022	SELL	$1.04 - $322.5 $23,816 - $7.39 Million	-22,900 Reduced 32.86%	46,800 $15,000
Q2 2022 Aug 12, 2022	SELL	$0.41 - $1.24 $12,956 - $39,184	-31,600 Reduced 31.19%	69,700 $11,000
Q1 2022 May 12, 2022	BUY	$0.62 - $1.17 $37,820 - $71,370	61,000 Added 151.36%	101,300 $4,000
Q4 2021 Feb 14, 2022	SELL	$1.09 - $1.89 $2,289 - $3,969	-2,100 Reduced 4.95%	40,300 $3,000
Q3 2021 Nov 10, 2021	BUY	$1.44 - $2.73 $29,232 - $55,419	20,300 Added 91.86%	42,400 $4,000
Q2 2021 Aug 11, 2021	BUY	$2.63 - $3.67 $58,123 - $81,107	22,100 New	22,100 $5,000
Q1 2021 May 14, 2021	SELL	$2.82 - $5.6 $209,244 - $415,520	-74,200 Closed	0 $0
Q4 2020 Feb 16, 2021	BUY	$2.09 - $3.09 $101,156 - $149,556	48,400 Added 187.6%	74,200 $5,000
Q1 2019 May 10, 2019	BUY	$2.0 - $4.4 $51,600 - $113,520	25,800 New	25,800 $24,000

92.6K

Ticker TCRT
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 216,182,000
Market Cap $443M
Description
Alaunos Therapeutics, Inc., a clinical-stage oncology-focused cell therapy company, develops adoptive TCR engineered T-cell therapies. It develops TCR Library, which is in Phase I/II clinical trial for ten TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancrea...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.